Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
PRGN-3007
/
Precigen
Welcome,
Profile
Billing
Logout
Diseases
Trials
Trials
News
|||
|||||||
PRGN-3007
/
Precigen
New P1 trial, CAR T-Cell Therapy, Metastases:
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
(clinicaltrials.gov) - Jan 23, 2023
P1
, N=88, Recruiting,
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
||||||||||
PRGN-3007
/
Precigen
A Phase1/1b Dose Escalation/Dose Expansion Study of Prgn-3007 Ultracar-T Cells in Patients with Advanced Hematologic and Solid Tumor Malignancies
(ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_4715;
All subjects will be followed for adverse events, CAR-T-related toxicities, disease response and PRGN-3007 cell expansion and persistence. In addition, the mechanisms of safety and effectiveness of PRGN-3007 cells will be evaluated with correlative assays of specific immune response pathways.
||||||||||
PRGN-3005
/
Precigen
Preclinical Evaluation of Prgn-3007, a Non-Viral, Multigenic, Autologous ROR1 Ultracar-T® Therapy with Novel Mechanism of Intrinsic PD-1 Blockade for Treatment of Hematological and Solid Cancers
(GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_3277;
P1
Data shown is from 8 mice/group at the start of the study. * p<0.05, ***p<0.001; log rank test.
||
||||||||
PRGN-3007
/
Precigen
$PGEN PRGN-3007 #ASH21 trial design
(Twitter) - Nov 4, 2021
||
||||||||
PRGN-3007
/
Precigen
$PGEN PRGN-3007 #ASH21
(Twitter) - Nov 4, 2021